Venus Medtech develops internationally advanced artificial cardiovascular valve systems with commercial applications. Led by Co-founder and CEO Eric Zi, the company is located in the Hangzhou National Hi-tech Development Zone. It has pioneered production of new valve models, including a pre-loading transcatheter valve system and the self-expanding transcatheter pulmonary valve system (VenusP-Valve). The company intends to use new funding to invest in R&D, production and expansion of its sales network. Since 2013 Venus Medtech has received investments from Qiming Venture Partners, Sequoia China and Goldman Sachs. The article does not disclose revenue or other operating metrics. Venus Medtech is a Hangzhou, China–based developer of transcatheter cardiac valve products led by General Manager Zi Zhenjun. The company has developed the Venus A‑Valve, a transcatheter aortic valve with independent intellectual property that meets China Food and Drug Administration clinical requirements. It is advancing the Venus P‑Valve for patients with severe pulmonary regurgitation after Tetralogy of Fallot repair; that device has entered the clinical stage and patient enrollment for its trial is nearly completed. Venus Medtech planned to start patient enrollment for an EU approval–oriented clinical research program in the first half of 2016. The company says the investment will support R&D and commercialization of its cardiac valve products. Existing backers include Qiming Venture Partners, Sequoia Capital China and Dinova Venture Capital.

Total raised

$37M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2016